The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors.
 
S. Gail Eckhardt
Stock and Other Ownership Interests - Entremed
Honoraria - Boehringer Ingelheim; Janssen Oncology; Kyowa Hakko Kirin; Lilly/ImClone
Consulting or Advisory Role - Onconova Therapeutics; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); OncoMed (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Genentech; Kyowa Hakko Kirin; Lilly/ImClone; Sanofi
 
William Larry Gluck
No Relationships to Disclose
 
Martin Gutierrez
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Essenex (Inst); Gilead Sciences (Inst); Kyronharm (Inst); Novartis (Inst)
 
Christine Peterson
Employment - Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals
 
Ely Benaim
Employment - Rexahn Pharmaceuticals
Leadership - Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals